Abstract
Background
The use of standardized tools and objective measurements is essential to test the effectiveness of new drugs or rehabilitative protocols. Friedreich’s ataxia (FRDA) patients with severe disease are often unable to perform the quantitative measurement tests currently used.
Aim
The purpose of our study was to develop an easy-to-use application, for touchscreen devices, able to quantify the degree of upper limb movement impairment in patients with severe Friedreich’s ataxia. The APP, which we named “Twelve-Red-Squares App-Coo-Test” (12-RSACT), assesses the upper limb ataxia by measuring the test execution time.
Methods
All patients were clinically evaluated using the Composite Cerebellar Functional Severity (CCFS) and the Scale for the Assessment and Rating of Ataxia (SARA). We recruited 92 healthy subjects and 36 FRDA patients with a SARA mean value of 28.8.1 ± 8.2. All participants in our study underwent upper limb movement assessment using the new 12-RSACT, the Click Test, and a well-established system, i.e., the Nine-Hole Peg Test (9HPT).
Results
We observed a strong linear correlation between the measurements obtained with the 12-RSACT and those obtained with 9HPT, Click Test, CCFS, and SARA. The 12-RSACT was characterized by excellent internal consistency and intra-rater and test-retest reliability. The minimal detectable change (MDC%) was excellent too. Additionally, the 12-RSACT turned out to be faster and easier to perform compared with the 9HPT.
Conclusion
The 12-RSACT is an inexpensive test and is easy to use, which can be administered quickly. Therefore, 12-RSACT is a promising tool to assess the upper limb ataxia in FRDA patients and even those with severe diseases.
Similar content being viewed by others
References
Di Donato S, Gellera C, Mariotti C (2001) The complex clinical and genetic classification of inherited ataxias. II. Autosomal recessive ataxias. Neurol Sci 22(3):219–228
Embiruçu EK, Martyn ML, Schlesinger D, Kok F (2009) Autosomal recessive ataxias: 20 types and counting. Arq Neuropsiquiatr 67:1143–1156
Marcotulli C, Fortuni S, Arcuri G, Tomassini B, Leonardi L, Pierelli F, Testi R, Casali C (2016) GIFT-1, a phase IIa clinical trial to test the safety and efficacy of IFNγ administration in FRDA patients. Neurol Sci 37(3):361–364
Leonardi L, Aceto MG, Marcotulli C, Arcuria G, Serrao M, Pierelli F, Paone P, Filla A, Roca A, Casali C (2017) A wearable proprioceptive stabilizer for rehabilitation of limb and gait ataxia in hereditary cerebellar ataxias: a pilot open-labeled study. Neurol Sci 38(3):459–463
Pandolfo M, Pastore A (2009) The pathogenesis of Friedreich ataxia and the structure and function of frataxin. J Neurol 256:9–17
Delatycki MB, Paris DB, Gardner RJ, Nicholson GA, Nassif N, Storey E, MacMillan JC, Collins V, Williamson R, Forrest SM (1999) Clinical and genetic study of Friedreich ataxia in an Australian population. Am J Med Genet 87:168–174
Delatycki MB, Knight M, Koenig M, Cossee M, Williamson R, Forrest SM (1999) G130V, a common FRDA point mutation appears to have arisen from a common founder. Hum Genet 105:343–346
Cossée M, Dürr A, Schmitt M, Dahl N, Trouillas P, Allinson P et al (1999) Friedreich’s ataxia: point mutations and clinical presentation of compound heterozygotes. Ann Neurol 45(2):200–206
Pelliccia V, Ferranti S, Mostardini R, Grosso S (2019) A case of Friedreich ataxia in an adolescent with 16p11.2 microdeletion syndrome. Neurol Sci. https://doi.org/10.1007/s10072-019-04075-z
Daiou C, Christodoulou K, Xiromerisiou G, Panas M, Dardiotis E, Kladi A, Speletas M, Ntaios G, Papadimitriou A, Germenis A, Hadjigeorgiou GM (2010) Absence of aprataxin gene mutations in a Greek cohort with sporadic early onset ataxia and normal GAA triplets in frataxin gene. Neurol Sci 31(3):393–397
Federico A (2004) Ataxia with isolated vitamin E deficiency: a treatable neurologic disorder resembling Friedreich’s ataxia. Neurol Sci 25(3):119–121
Campuzano V, Montermini L, Moltò MD, Pianese L, Cossée M, Cavalcanti F et al (1996) Friedreich’s ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science 271(5254):1423–1427
Heidari MM, Houshmand M, Hosseinkhani S, Nafissi S, Scheiber-Mojdehkar B, Khatami M (2008) Association between trinucleotide CAG repeats of the DNA polymerase gene (POLG) with age of onset of Iranian Friedreich’s ataxia patients. Neurol Sci 29(6):489–493
Christodoulou K, Deymeer F, Serdaroğlu P, Özdemir C, Poda M, Georgiou DM et al (2001) Mapping of the second Friedreich’s ataxia (FRDA2) locus to chromosome 9p23-p11: evidence for further locus heterogeneity. Neurogenetics 3(3):127–132
Rajesh S et al (2002) The GAA triplet-repeat sequence in Friedreich ataxia shows a high level of somatic instability in vivo, with a significant predilection for large contractions. Hum Mol Genet 11(18):2175–2187
Sharma R, De Biase I, Gomez M, Delatycki MB, Ashizawa T, Bidichandani SI (2004) Friedreich ataxia in carriers of unstable borderline GAA triplet-repeat alleles. Ann Neurol 56:898–901
Santos R, Lefevre S, Sliwa S, Seguin A, Camadro J, Lesuisse E (2010) Friedreich ataxia: molecular mechanisms, redox considerations, and therapeutic opportunities. Antioxid Redox Signal 13:651–690
Bulteau AL, Dancis A, Gareil M, Montagne JJ, Camadro JM, Lesuisse E (2007) Oxidative stress and protease dysfunction in the yeast model of Friedreich ataxia. Free Radic Biol Med 42:1561–1570
Clemm von Hohenberg C, Schocke MF, Wigand MC, Nachbauer W, Guttmann CR, Kubicki M, Shenton ME, Boesch S, Egger K (2013) Radial diffusivity in the cerebellar peduncles correlates with clinical severity in Friedreich ataxia. Neurol Sci 34(8):1459–1462
Parkinson MH, Boesch S, Nachbauer W, Mariotti C, Giunti P (2013) Clinical features of Friedreich’s ataxia: classical and atypical phenotypes. J Neurochem 126(1):103–117
Armani M, Zortea M, Pastorello E, Lombardi S, Tonello S, Zuliani L, Rigoni MT, Trevisan CP (2006) Friedreich’s ataxia: clinical heterogeneity in two sisters. Neurol Sci 27(2):140–142
Bürk K, Mälzig U, Wolf S, Heck S, Dimitriadis K, Schmitz-Hübsch T, Hering S, Lindig TM, Haug V, Timmann D, Degen I (2009) Comparison of three clinical rating scales in Friedreich ataxia (FRDA). Mov Disord 24(12):1779–1784
Bürk K, Schulz SR, Schulz JB (2013) Monitoring progression in Friedreich ataxia (FRDA): the use of clinical scales. J Neurochem 126(1):18–124
Schmitz-Hübsch T, du Montcel ST, Baliko L, Berciano J, Boesch S, Depondt C, Giunti P, Globas C, Infante J, Kang JS et al (2006) Scale for the assessment and rating of ataxia: development of a new clinical scale. Neurology 66:1717–1720
Saute JAM, Donis KC et al (2012) Ataxia rating scales-psychometric profiles, natural history and their application in clinical trials. Cerebellum 11(2):488–504
Schmitz-Hübsch T, Fimmers R, Rakowicz M, Rola R, Zdzienicka E, Fancellu R et al (2010) Responsiveness of different rating instruments in spinocerebellar ataxia patients. Neurology 74:678–684
Schmitz-Hübsch T, Giunti P, Stephenson DA, Globas C, Baliko L, Saccà F et al (2008) SCA Functional Index - usefulness of a compound performance measure in spinocerebellar ataxia patients. Neurology. 71:486–492
Du Montcel S, Charles P, Ribai P (2008) Composite cerebellar functional severity score: validation of a quantitative score of cerebellar impairment. Brain 131:1352–1361
Mathiowetz V, Weber K, Kashman N, Volland G (1985) Adult norms for the Nine Hole Peg Test of finger dexterity. Occup Ther J Res 5(1):24–38
Oxford Grice K, Vogel KA, Le V, Mitchell A, Muniz S, Vollmer MA (2003) Adult norms for a commercially available Nine Hole Peg Test for finger dexterity. Am J Occup Ther 57(5):570–573
Saccà F et al (2016) Long-term effect of epoetin alfa on clinical and biochemical markers in Friedreich ataxia. Mov Disord 31:734–741
Patel M et al (2019) Open-label pilot study of oral methylprednisolone for the treatment of patients with Friedreich ataxia. Muscle Nerve 60(5):571–575
Pandolfo M et al (2014) Deferiprone in Friedreich ataxia: a 6-month randomized controlled trial. Ann Neurol 76:509–521
Corben LA et al (2010) A comparison of three measures of upper limb function in Friedreich ataxia. J Neurol 257:518–523
Tai G et al (2017) How does performance of the Friedreich Ataxia Functional Composite compare to rating scales? J Neurol 264:1768–1776
Arcuria G, Marcotulli C, Galasso C, Pierelli F, Casali C (2019) 15-White Dots APP-Coo-Test: a reliable touch-screen application for assessing upper limb movement impairment in patients with cerebellar ataxias. J Neurol 266(7):1611–1622
Solari A, Radice D, Manneschi L et al (2005) The multiple sclerosis functional composite: different practice effects in the three test components. J Neurol Sci 228:71–74
Serrao M, Pierelli F, Ranavolo A, Draicchio F, Conte C, Casali C et al (2012) Gait pattern in inherited cerebellar ataxias. Cerebellum 11(1):194–211
Portney LG, Watkins MP (2009) Foundations of clinical research: applications to practice, 3rd edn. Prentice Hall, Upper Saddle River
Harvill L (1991) Standard error of measurement. Educ Meas 10:33–41
Donoghue D, Stokes EK (2009) How much change is true change? The minimum detectable change of the Berg Balance Scale in elderly people. J Rehabil Med 41:343–346
Haley SM, Fragala-Pinkham MA (2006) Interpreting change scores of tests and measures used in physical therapy. Phys Ther 86:735–743
Long A, Napierala JS, Polak U, Hauser L, Koeppen AH, Lynch DR et al (2017) Somatic instability of the expanded GAA repeats in Friedreich’s ataxia. PLoS One 12(12):e0189990
De Biase I, Rasmussen A, Endres D, Al-Mahdawi S, Monticelli A, Cocozza S (2007) Progressive GAA expansions in dorsal root ganglia of Friedreich’s ataxia patients. Ann Neurol 61:55–60
Filla A, De Michele G, Cavalcanti F, Pianese L, Monticelli A, Campanella G, Cocozza S (1996) The relationship between trinucleotide (GAA) repeat length and clinical features in Friedreich ataxia. Am J Hum Genet 59(3):554–560
Acknowledgments
We thank the patients and healthy subjects who participated in our study.
Author information
Authors and Affiliations
Contributions
All authors contributed to the study conception and design. Material preparation was performed by Giuseppe Arcuria and Raffaele Amuso. Data collection and analysis were performed by Giuseppe Arcuria, Christian Marcotulli, and Claudio Galasso. Giuseppe Arcuria and Giuliano Dattilo did the statistical analyses. All authors contributed to interpretation of the results. The first draft of the manuscript was written by Giuseppe Arcuria and Giuliano Dattilo. Review and supervision were performed by Francesco Pierelli and Carlo Casali. All authors commented on previous versions of the manuscript and read and approved the final manuscript.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical approval
All the procedures performed in this study were in accordance with ethical standards laid down in 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. All patients gave their written informed consent before study enrollment.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Arcuria, G., Marcotulli, C., Amuso, R. et al. Developing an objective evaluating system to quantify the degree of upper limb movement impairment in patients with severe Friedreich’s ataxia. Neurol Sci 41, 1577–1587 (2020). https://doi.org/10.1007/s10072-020-04249-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10072-020-04249-0